With HAVEL LABS, a unique campus is being developed in Berlin-Spandau. Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) guidelines, can be effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in accordance with German Genetic Engineering Safety Regulations.
Spexis sells antibiotics programme to Basilea
Latest NewsMacrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.
Finnish Enifer Oy secures €12m grant to scale up
Latest NewsMicrobial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.
Mogu Srl raises €11m to scale mycelium technology
Latest NewsItalian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the European Circular Bioeconomy Fund (ECBF VC)
Novo Nordisk Foundation in US$25m partnership with CARB-X
Latest NewsNovo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.
Novartis AG to buy immunology specialist Calypso Biotech BV
Latest NewsCalypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypsos US$250m upfront upon closing plus of up to US$175.
GLP1 agonists: FDA investigates suicide risk
Latest NewsFollowing in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Latest NewsBoehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
miRNA specialist Resalis Therapeutics Srl raises €10m in Series A financing
Latest NewsItalian Resalis Therapeutics Srl has baged €10m in a Series A financing led by Sunstone Life Science Ventures to complete a Phase I study for RES-010 in obesity.
Roche presents restistance-breaking antibiotic
Latest NewsHoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.
The future finds a new home: HAVEL LABS
Sponsored PublicationsWith HAVEL LABS, a unique campus is being developed in Berlin-Spandau. Spanning over 20,000 m2, this space is designed for forward-thinking work environments. Modern industrial workplaces and logistics concepts, aligned with GMP (Good Manufacturing Practice) guidelines, can be effortlessly realised on the premises, as can laboratories ranging from safety level S1 to S3 in accordance with German Genetic Engineering Safety Regulations.